Publication | Open Access

Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy

Hematological MalignancyLymphoid NeoplasiaMedicinePrognostic ValueImmunologyPathologyImmune SurveillanceAutoimmunityImmune Checkpoint InhibitorImmunotherapyOncologySoluble Interleukin-2 Receptor